CLINUVEL’s Chair Willem Blijdorp shares his insights on the foundations of the Company and his role as Chair. In this first of three Insider Insights, captured in a discussion between Mr Blijdorp and Professor Kitty Koelemeijer, the history of the business and its position as a public company (ASX: CUV) are in focus.
CLINUVEL has today announced that its drug afamelanotide was well tolerated by the first three arterial ischaemic stroke (AIS) patients enrolled in a world first clinical trial (CUV801). Watch our new video explaining the pathology and treatment of stroke.
CLINUVEL PHARMACEUTICALS LTD (Company) today announces that in light of the restrictions on public gatherings and on international travel and in line with temporary amendments to the Corporations Act 2001 (Cth) in response to the COVID-19 pandemic, the Company’s 2021 Annual General Meeting (AGM) of shareholders will be held as a virtual (online) meeting
CLINUVEL’s Head of Investor Relations, Mr Malcom Bull, leads a discussion with CFO Mr Darren Keamy and CEO Dr Philippe Wolgen follow the release of the Company’s financial results for the year ended 30 June 2021. Held on 26 August 2021 at 1800 Melbourne time.